Market Overview

UPDATE: Canaccord Genuity Raises PT on Biogen Idec on Tecfidera Approval

Related BIIB
Biogen Idec, Inc. Suddenly Struggling To Keep Up With The Biotech Joneses
Biogen Reports PLEGRIDY Two-Year Data Confirms Maintenance of Efficacy, Safety in MS Patients
Don't Panic Over Recent Tech Turmoil (Fox Business)

In a report published Thursday, Canaccord Genuity analyst Ritu Baral reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB), and raised the price target from $187.00 to $200.00.

In the report, Baral noted, “Reiterate BUY, increasing target to $200 on approval of Tecfidera (Tec), BIIB's new blockbuster potential oral MS drug with sparkling clean label. BIIB guidance implies strong confidence in the Tec launch. We have confidence in the initial phase of launch on high levels of community patient warehousing.We see long-term value and blockbuster potential in Tec, Tysabri and the hemophilia franchise. Our $200 price target is DCF-based.”

Biogen Idec closed on Wednesday at $182.68.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2014Deutsche BankMaintainsBuy
Jul 2014JefferiesMaintainsBuy
Jul 2014Credit SuisseMaintainsOutperform

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (BIIB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional